Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03987672 · ClinicalTrials.gov registry record · NA
Study to Intervene With Nutrition for Gastroparesis
A NA study, sponsored by Stanford University.
- Terminated
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT03987672: Clinical Trial NA study, sponsored by Stanford University.
NCT03987672 is a NA study that was terminated before completion, run by Stanford University. The registered enrollment target is 5 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03987672, a NA study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
The study is a self-controlled study in which we will assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula in patients with gastroparesis, relative to their pre-enrollment nutritional diet regimen.
Primary Outcome
9-item measure of severity of gastroparesis symptoms on a scale of 0-5 (none to worst) Higher values represent a worse outcome.
Interventions
- DIETARY_SUPPLEMENT Assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2022-08-18 |
| Phase | NA |
Why NCT03987672 stopped before completion
NCT03987672 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula is the first listed.
NCT03987672 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03987672 about?
NCT03987672 is a clinical study titled "Study to Intervene With Nutrition for Gastroparesis". The study is a self-controlled study in which we will assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula in patients with gastroparesis, relative to their pre-enrollment nutritional diet regimen.
What is the current status of trial NCT03987672?
This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2019-08-01. Estimated completion is 2022-08-18.
What interventions are being tested in trial NCT03987672?
The interventions under investigation include: Assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03987672?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03987672's enrollment target sits among peer trials
5 1988th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI